Literature DB >> 25038617

New expensive treatments for hepatitis C infection.

Troyen Brennan1, William Shrank1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25038617     DOI: 10.1001/jama.2014.8897

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  24 in total

1.  Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?

Authors:  Alan Lyles
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

2.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

3.  Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.

Authors:  Thomas Ward; Jason Gordon; Beverley Jones; Hayley Bennett; Samantha Webster; Anupama Kalsekar; Yong Yuan; Michael Brenner; Phil McEwan
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

4.  Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.

Authors:  Philip R Spradling; Jian Xing; Loralee B Rupp; Anne C Moorman; Stuart C Gordon; Mei Lu; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Scott D Holmberg
Journal:  J Clin Gastroenterol       Date:  2018-08       Impact factor: 3.062

5.  Is response-guided therapy being applied in the clinical setting? The hepatitis C example.

Authors:  Jennifer B Harris; Melea A Ward; Phil Schwab
Journal:  Am Health Drug Benefits       Date:  2015-02

6.  Expression of the novel hepatitis C virus core+1/ARF protein in the context of JFH1-based replicons.

Authors:  Ioly Kotta-Loizou; Ioannis Karakasiliotis; Niki Vassilaki; Panagiotis Sakellariou; Ralf Bartenschlager; Penelope Mavromara
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

7.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

8.  Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.

Authors:  Yamini Kalidindi; Jeah Jung; Roger Feldman; Thomas Riley
Journal:  JAMA Netw Open       Date:  2020-07-01

9.  Addressing viral resistance through vaccines.

Authors:  Catherine Laughlin; Amanda Schleif; Carole A Heilman
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

10.  Estimating the Effect of Health Insurance on Personal Prescription Drug Importation.

Authors:  Andrew R Zullo; Chanelle J Howe; Omar Galárraga
Journal:  Med Care Res Rev       Date:  2016-08-03       Impact factor: 3.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.